Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 12/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338950 | 0.91 | ALDH1A1 (0.40) | DPP4DPP8ALPLDPP9ALDH1A1 | |
| SCHEMBL339703 | 0.79 | P2RX7 (0.45) | — | |
| SCHEMBL338577 | 0.78 | GSK3B (0.39) | DPP4DPP8DPP9ALDH1A1MAPT | |
| SCHEMBL339881 | 0.77 | GSK3B (0.36) | DPP4DPP8DPP9 | |
| SCHEMBL1911445 | 0.77 | P2RX7 (0.38) | DPP4DPP8TNKSTNKS2PARP2 | |
| SCHEMBL338848 | 0.77 | P2RX7 (0.38) | DPP4DPP8TNKSTNKS2PARP2 | |
| SCHEMBL1912414 | 0.77 | P2RX7 (0.38) | DPP4DPP8TNKSTNKS2PARP2 | |
| SCHEMBL339320 | 0.76 | DPP4 (0.41) | DPP4DPP8DPP9HPGD | |
| SCHEMBL339777 | 0.76 | EPHX2 (0.38) | DPP4DPP8DPP9 | |
| SCHEMBL339259 | 0.73 | CHRM3 (0.33) | DPP4TNKSTNKS2PARP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | OAT, GPR119, OTC | DPP4 120/4885DPP8 403/4885ALPL 1177/4885 |
| US-20090253689-A1 | Organic Compounds | OAT, GPR119, OTC | DPP4 120/4885DPP8 403/4885ALPL 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.